Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.
作者信息
Sobh Mohamad, Michallet Mauricette, Dubois Valérie, Iacobelli Simona, Koster Linda, Van Biezen Anja, Fegueux Nathalie, Tabrizi Reza, Finke Jürgen, El-Cheikh Jean, Schipperus Martin, Meijer Ellen, von dem Borne Peter, Petersen Eefke, Russell Nigel, Tholouli Eleni, Passweg Jakob, Garban Frédéric, Maertens Johan, Chevalier Patrice, Maillard Natacha, Volin Liisa, Francois Sylvie, Lioure Bruno, Beguin Yves, Gluckman Eliane, Ruggeri Annalisa, Garderet Laurent, Kröger Nicolaus
机构信息
Hematology, Centre Hospitalier Lyon-Sud, Pierre-Benite, France.
Hematology, Centre Hospitalier Lyon-Sud, Pierre-Benite, France
出版信息
Haematologica. 2017 Jul;102(7):e271-e274. doi: 10.3324/haematol.2017.165399. Epub 2017 Apr 20.
Abstract
摘要
相似文献
1
Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.
Haematologica. 2017 Jul;102(7):e271-e274. doi: 10.3324/haematol.2017.165399. Epub 2017 Apr 20.
2
Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.
Haematologica. 2016 Jun;101(6):773-80. doi: 10.3324/haematol.2015.138180. Epub 2016 Mar 11.
3
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry.
Biol Blood Marrow Transplant. 2013 Jun;19(6):940-8. doi: 10.1016/j.bbmt.2013.03.012. Epub 2013 Mar 26.
4
Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):379-86. doi: 10.1016/j.clml.2016.03.001. Epub 2016 Mar 30.
5
Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Biol Blood Marrow Transplant. 2015 Jun;21(6):1054-8. doi: 10.1016/j.bbmt.2015.02.012. Epub 2015 Feb 20.
6
Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic.
Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):349-357.e2. doi: 10.1016/j.clml.2015.03.016. Epub 2015 Apr 2.
7
Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT.
Haematologica. 2016 Sep;101(9):1120-7. doi: 10.3324/haematol.2015.138917. Epub 2016 May 26.
8
Long-term survival after allogeneic stem cell transplantation for advanced stage multiple myeloma.
Br J Haematol. 2014 Aug;166(4):616-8. doi: 10.1111/bjh.12881. Epub 2014 Apr 4.
9
High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Oncotarget. 2016 May 10;7(19):27255-66. doi: 10.18632/oncotarget.8463.
10
The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.
Biol Blood Marrow Transplant. 2014 Aug;20(8):1211-6. doi: 10.1016/j.bbmt.2014.04.027. Epub 2014 May 2.
引用本文的文献
1
Haploidentical Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Extramedullary Multiple Myeloma: A Conditioning Regimen Combining Selinexor and Helical Tomotherapy-A Case Report and Literature Review.
J Blood Med. 2025 Apr 2;16:177-185. doi: 10.2147/JBM.S495256. eCollection 2025.
2
Historical Perspective of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
Acta Haematol. 2025;148(3):315-329. doi: 10.1159/000542704. Epub 2024 Nov 25.
3
Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years.
Front Oncol. 2024 Jul 31;14:1341631. doi: 10.3389/fonc.2024.1341631. eCollection 2024.
4
Allogeneic stem cell transplantation in multiple myeloma: is there still a place?
Front Oncol. 2024 Jun 4;14:1402106. doi: 10.3389/fonc.2024.1402106. eCollection 2024.
5
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
Bone Marrow Transplant. 2022 Nov;57(11):1664-1670. doi: 10.1038/s41409-022-01777-5. Epub 2022 Aug 18.
6
Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma.
Oncol Ther. 2022 Jun;10(1):105-122. doi: 10.1007/s40487-022-00195-3. Epub 2022 Apr 4.
7
Allogeneic Stem Cell Transplantation in Multiple Myeloma.
Cancers (Basel). 2021 Dec 23;14(1):55. doi: 10.3390/cancers14010055.
8
Allogeneic Stem Cell Transplantation in Patients with High-Risk Multiple Myeloma: Utopia or Continuous Challenge in Aiming for Cure?
Curr Treat Options Oncol. 2021 Jun 10;22(8):65. doi: 10.1007/s11864-021-00864-x.
9
Allogeneic Transplantation in Multiple Myeloma-Does It Still Have a Place?
J Clin Med. 2020 Jul 10;9(7):2180. doi: 10.3390/jcm9072180.
本文引用的文献
1
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
2
Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.
Leuk Lymphoma. 2017 Apr;58(4):797-808. doi: 10.1080/10428194.2016.1228926. Epub 2016 Sep 21.
3
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
4
Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT.
Haematologica. 2016 Sep;101(9):1120-7. doi: 10.3324/haematol.2015.138917. Epub 2016 May 26.
5
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.
6
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.
Leukemia. 2016 Oct;30(10):2047-2054. doi: 10.1038/leu.2016.101. Epub 2016 Apr 27.
7
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.
8
Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2015 Jul;21(7):1291-8. doi: 10.1016/j.bbmt.2015.02.015. Epub 2015 Feb 21.
9
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
10
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18.
Zotero 插件